Daily Cosmetic Research Analysis
A randomized, evaluator-blinded trial showed that a cross-linked hyaluronic acid gel (MaiLi-E) significantly improved chin retrusion with acceptable safety and durability to 12 months. An in vitro study mapped the minimum recombinant human hyaluronidase doses needed to dissolve 22 hyaluronic acid fillers, guiding safer reversal of complications. Multi-omics profiling revealed phenoxyethanol’s antimicrobial mechanisms against Cutibacterium acnes phylotypes, informing acne-oriented cosmetic formul
Summary
A randomized, evaluator-blinded trial showed that a cross-linked hyaluronic acid gel (MaiLi-E) significantly improved chin retrusion with acceptable safety and durability to 12 months. An in vitro study mapped the minimum recombinant human hyaluronidase doses needed to dissolve 22 hyaluronic acid fillers, guiding safer reversal of complications. Multi-omics profiling revealed phenoxyethanol’s antimicrobial mechanisms against Cutibacterium acnes phylotypes, informing acne-oriented cosmetic formulation.
Research Themes
- Aesthetic injectables: efficacy and safety
- Filler complication management and hyaluronidase dosing
- Cosmetic microbiology and preservative mechanisms
Selected Articles
1. Efficacy and Safety of Chin Augmentation Using MaiLi-E, a Lidocaine-Containing Cross-Linked Sodium Hyaluronate Gel.
In a multicenter randomized, evaluator-blinded, delayed-treatment controlled trial (n=159), MaiLi‑E significantly improved chin retrusion at 6 months (64.2% responders vs 20.8% control; P<0.0001), with high participant-rated aesthetic improvement (91.5%) and durability to 12 months. Adverse events occurred in 64.8% overall, but treatment-related AEs were low (5.0%).
Impact: This CONSORT-like randomized evidence directly informs efficacy, durability, and safety of a new hyaluronic acid filler for chin augmentation. It fills a clinical evidence gap in aesthetic injectables with blinded evaluation and a delayed-treatment control.
Clinical Implications: Supports MaiLi‑E as an effective option for mild-to-severe chin retrusion with benefits lasting up to 12 months; informs patient counseling, follow-up scheduling, and risk–benefit discussions based on blinded outcomes and AE rates.
Key Findings
- Responder rate at 6 months: 64.2% (MaiLi‑E) vs 20.8% (control), P<0.0001
- Participant Global Aesthetic Improvement: 91.5% (MaiLi‑E) vs 0.0% (control)
- Efficacy maintained in most participants at 12 months
- Adverse events in 64.8% overall; treatment-related AEs in 5.0%
Methodological Strengths
- Prospective multicenter randomized design with evaluator blinding
- Delayed-treatment control minimizing ethical concerns and assessor bias
Limitations
- No active comparator against other fillers; generalizability limited to chin retrusion
- Patient blinding not described; long-term safety beyond 12 months not assessed
Future Directions: Head-to-head trials versus other HA fillers, inclusion of diverse populations, standardized patient-reported outcomes, and longer-term safety surveillance.
2. Transcriptomic and metabolomic analyses of the antimicrobial activity of phenoxyethanol against phylotype IA1 and II Cutibacterium acnes.
Phenoxyethanol inhibited Cutibacterium acnes IA1 and II phylotypes with an MIC of 0.5% (v/v), with stronger sub-MIC inhibition of the II strain. Multi-omics showed membrane disruption, broad metabolic pathway perturbations, downregulation of porphyrin metabolism genes, and phylotype-specific shifts in glycolysis and the Wood–Werkman cycle.
Impact: Elucidating phylotype-specific antimicrobial mechanisms links a widely used cosmetic preservative to acne-relevant pathways (porphyrin metabolism), guiding formulation choices and potential therapeutic repurposing.
Clinical Implications: Suggests phenoxyethanol could reduce C. acnes burden and porphyrin-associated inflammation; however, clinical efficacy, tolerability on human skin, and optimal concentrations require validation.
Key Findings
- MIC against C. acnes IA1 and II phylotypes was 0.5% (v/v)
- Sub-MIC inhibition was stronger for the II strain (CCSM0331)
- RNA-seq and metabolomics showed membrane disruption and metabolic pathway perturbations
- Porphyrin metabolism gene expression was significantly reduced
- Glycolysis and Wood–Werkman cycle inhibited in II but enhanced in IA1
Methodological Strengths
- Integrated transcriptomic and metabolomic profiling
- Comparison across two clinically relevant C. acnes phylotypes with MIC determination
Limitations
- In vitro study with limited number of strains; clinical translation uncertain
- Formulation-relevant concentrations and skin tolerability not evaluated in humans
Future Directions: Validate effects in skin models and clinical studies, define safe and effective concentrations, and assess phylotype-resolved responses in vivo.
3. Identifying Minimum Single Dose of Recombinant Human Hyaluronidase for In Vitro Dissolution of Twenty-Two Hyaluronic Acid Fillers.
Across 22 commercially available HA fillers, the minimum single dose of recombinant human hyaluronidase to achieve complete dissolution within 6 hours ranged from 2.5 to 140 units per 0.2 ml, with consistent results across triplicate trials. Several Juvéderm and Restylane products required ≤20 U, whereas RHA 2/3/4, Belotero Volume, Juvéderm Ultra XC/Volux, Restylane Kysse, and Revanesse Versa needed ≥120 U.
Impact: Provides quantitative, product-specific hyaluronidase dosing guidance that can reduce overuse and adverse effects during urgent management of filler complications.
Clinical Implications: Clinicians can tailor hyaluronidase dosing by filler type when reversing overcorrection, Tyndall effect, or vascular compromise, potentially improving safety and efficiency.
Key Findings
- Minimum single RHH dose per 0.2 ml ranged from 2.5 to 140 units across 22 fillers
- Least resistant fillers (e.g., Volbella, Vollure, Skinvive, Restylane-L/Lyft/Silk) required ≤20 units
- Most resistant fillers (RHA 2/3/4, Belotero Volume, Juvéderm Ultra XC/Volux, Restylane Kysse, Revanesse Versa) required ≥120 units
- Results were consistent across three independent trials per filler
Methodological Strengths
- Standardized in vitro protocol with predefined dose titrations and triplicate trials
- Objective documentation via serial photography and video confirmation of dissolution
Limitations
- In vitro conditions may not reflect tissue diffusion and in vivo enzymatic kinetics
- No assessment of clinical outcomes, adverse reactions, or patient-level variability
Future Directions: Validate dosing in ex vivo tissue models and clinical settings; integrate rheological properties to predict dose; develop bedside dosing algorithms.